An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM)-Reference-Cited by-同舟云学术

An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM)

Published:2016-06-08 Issue:8 Volume:91 Page:806-811
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Leleu Xavier¹,Terpos Evangelos²,Sanz Ramón García³,Cooney Julian⁴,O'Gorman Peter⁵,Minarik Jiri⁶,Greil Richard⁷,Williams Catherine⁸,Gray Diep⁹,Szabo Zsolt¹⁰

Affiliation:

1. Department of Haematology; Hôpital Claude Huriez; Lille France

2. Department of Clinical Therapeutics; National and Kapodistrian University of Athens, School of Medicine; Athens Greece

3. Department of Hematology; Hospital Universitario De Salamanca; Salamanca Spain

4. Department of Hematology; Royal Perth Hospital and University of Western Australia; Crawley Western Australia Australia

5. Mater University Hospital, UCD School of Medicine and Medical Science; Dublin Ireland

6. Department of Hemato-Oncology; Medical Faculty of Palacky University and University Hospital Olomouc; Olomouc Czech Republic

7. IIIrd Medical Department; Paracelsus Medical University Salzburg and Salzburg Cancer Research Institute; Salzburg Austria

8. Center for Clinical Hematology; Nottingham University Hospitals; Nottingham United Kingdom

9. Consultant Biostatistician; Cambridge United Kingdom

10. Research and Development; Amgen (Europe) GmbH; Zug Switzerland

Funder

Amgen (Europe)

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.24416/fullpdf

Reference27 articles.

1. Novel targeted therapies and combinations for the treatment of multiple myeloma;Agarwal;Cardiovasc Hematol Disord Drug Targets,2013

2. Current treatment landscape for relapsed and/or refractory multiple myeloma;Dimopoulos;Nat Rev Clin Oncol,2015

3. Improved survival in multiple myeloma and the impact of novel therapies;Kumar;Blood,2008

4. Managing multiple myeloma: The emerging role of novel therapies and adapting combination treatment for higher risk settings;Richardson;Br J Haematol,2011

5. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: Consensus statement;Dimopoulos;Leukemia,2011

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review;Frontiers in Oncology;2023-02-07

2. CAR-T cell combination therapy: the next revolution in cancer treatment;Cancer Cell International;2022-11-24

3. Long-acting granulocyte colony-stimulating factor in primary prophylaxis of early infection in patients with newly diagnosed multiple myeloma;Supportive Care in Cancer;2022-01-22

4. Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma;Supportive Care in Cancer;2021-05-14

5. Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients;Frontiers in Oncology;2021-02-15